Budget Impact of Atezolizumab for The Treatment of 2nd Line Non-Small Cell Lung Cancer (NSCLC) After Failure with Platinum Containing Chemotherapy in Greece
Oct 1, 2017, 00:00 AM
10.1016/j.jval.2017.08.150
https://www.valueinhealthjournal.com/article/S1098-3015(17)30484-9/fulltext
Section Title :
Disease-Specific Studies
Section Order :
127
First Page :
A423
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(17)30484-9&doi=10.1016/j.jval.2017.08.150